Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Anna Pawłowska, Dorota Suszczyk, Rafał Tarkowski, Roman Paduch, Jan Kotarski & Iwona Wertel. (2020) Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients. Cancer Management and Research 12, pages 9691-9709.
Read now
Read now
Timothy Hadley, Scott Gillespie, Hillary Espinoza, Jarod Prince, Henning Gronbaek, Shanmuganathan Chandrakasan, Subra Kuguthasan, Vasantha L. Kolachala & Nitika A. Gupta. (2020) Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. Autoimmunity 53:5, pages 253-260.
Read now
Read now
Ola G. Behairy, Eman G. Behiry, Manal S. El Defrawy & Ahmed N. El Adly. (2020) Diagnostic value of soluble programmed cell death protein-1 in type-1 autoimmune hepatitis in Egyptian children. Scandinavian Journal of Clinical and Laboratory Investigation 80:1, pages 59-65.
Read now
Read now
Albert J. Czaja. (2019) Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity 52:4, pages 144-160.
Read now
Read now
Albert J. Czaja. (2018) Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Review of Gastroenterology & Hepatology 12:6, pages 547-564.
Read now
Read now
Articles from other publishers (31)
Mingrong Ou, Weiming Zhang, Wen Zhang, Jianmin Guo, Rui Huang, Jian Wang, Jiacheng Liu, Juan Xia, Chao Wu, Yijia Zhu & Yuxin Chen. (2024) Soluble Programmed Cell Death 1 Protein Is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients. ACS Omega 9:14, pages 16716-16724.
Crossref
Crossref
Fanny Chovet, Anne-Sophie Passot, Quentin Mangon, Paul Rouzaire & Aurore Dougé. (2024) Le taux circulant de PD-L1 : un biomarqueur émergent de réponse aux inhibiteurs de checkpoints immunitaires. Bulletin du Cancer 111:4, pages 416-427.
Crossref
Crossref
Nitsan Haham, Omri Zveik, Ariel Rechtman, Livnat Brill & Adi Vaknin-Dembinsky. (2024) Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD. Journal of Neuroimmunology 388, pages 578289.
Crossref
Crossref
Junko Tanizaki, Hiroaki Kuroda, Toshihide Yokoyama, Makoto Takahama, Hiroyasu Shoda, Atsushi Nakamura, Yoshitaka Kitamura, Nobuaki Mamesaya, Yoshihisa Kadota, Kenji Sawa, Kyoichi Okishio, Morihito Okada, Chihiro Suminaka, Kenta Noda, Kazuko Sakai, Yasutaka Chiba, Kazuto Nishio, Kenji Chamoto, Tasuku Honjo, Nobuyuki Yamamoto, Kazuhiko Nakagawa & Hidetoshi Hayashi. (2023) Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy. JTO Clinical and Research Reports 4:12, pages 100590.
Crossref
Crossref
Akira Kado, Takeya Tsutsumi, Hiroshi Yotsuyanagi, Kazuhiko Ikeuchi, Kazuya Okushin, Kyoji Moriya, Kazuhiko Koike & Mitsuhiro Fujishiro. (2023) Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern. Journal of Gastroenterology 58:12, pages 1237-1251.
Crossref
Crossref
Amin Daei Sorkhabi, Erfan Komijani, Aila Sarkesh, Pedram Ghaderi Shadbad, Ali Aghebati-Maleki & Leili Aghebati-Maleki. (2023) Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice. Cell Communication and Signaling 21:1.
Crossref
Crossref
Xiuzhu Gao, Xiaomei Wang, Yazhe Guan, Liquan Wang, Yanhang Gao & Junqi Niu. (2023) Soluble immune checkpoints are elevated in patients with primary biliary cholangitis. European Journal of Medical Research 28:1.
Crossref
Crossref
Fan Li, Zheng Zhou, Lingbo Wang, Baoxiang Li, Meihui Jin, Jinjin Liu, Yun Chen, Yanhong He, Bingxuan Ren, Hongmei Shen & Lixiang Liu. (2023)
A study of programmed death‐1/programmed death ligand and iodine‐induced autoimmune thyroiditis in
NOD.H‐2h4
mice
. Environmental Toxicology 38:11, pages 2574-2584.
Crossref
Crossref
Thanos Tsaktanis, Mathias Linnerbauer, Lena Lößlein, Daniel Farrenkopf, Oliver Vandrey, Anne Peter, Ana Cirac, Tobias Beyer, Lucy Nirschl, Verena Grummel, Mark Mühlau, Matthias Bussas, Bernhard Hemmer, Francisco J Quintana & Veit Rothhammer. (2023) Regulation of the programmed cell death protein 1/programmed cell death ligand 1axis in relapsing-remitting multiple sclerosis. Brain Communications.
Crossref
Crossref
Jian Lu, Jing Wu, Lingxiang Mao, Huaxi Xu & Shengjun Wang. (2022) Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression. Cytokine & Growth Factor Reviews 67, pages 58-65.
Crossref
Crossref
Christoph Schultheiß, Silja Steinmann, Ansgar W. Lohse & Mascha Binder. (2022) B cells in autoimmune hepatitis: bystanders or central players?. Seminars in Immunopathology 44:4, pages 411-427.
Crossref
Crossref
Mingli Hu, Zhengrui You, You Li, Bingyuan Huang, Nana Cui, Rui Wang, Yiran Wei, Bo Li, Jubo Liang, Qiaoyan Liu, Yikang Li, Hanxiao Wang, Qiwei Qian, Jun Zhang, Ruiling Chen, Zhuwan Lyu, Yong Chen, Xiao Xiao, Min Lian, Ruqi Tang, Qi Miao, Qixia Wang & Xiong Ma. (2022) Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature. Clinical Reviews in Allergy & Immunology 63:3, pages 342-356.
Crossref
Crossref
Chie Miyabe, Yupeng Dong, Takaharu Ikeda, Kazuo Takahashi, Yoshishige Miyabe & Tamihiro Kawakami. (2021) Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis. Scientific Reports 11:1.
Crossref
Crossref
Zuzana Macek Jilkova, Marie Noelle Hilleret, Theophile Gerster, Nathalie Sturm, Marion Mercey-Ressejac, Jean-Pierre Zarski, Vincent Leroy, Patrice N. Marche, Charlotte Costentin & Thomas Decaens. (2021) Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease. Cells 10:10, pages 2671.
Crossref
Crossref
HaiXia Li, Chao Zheng, Jinming Han, Jie Zhu, Shan Liu & Tao Jin. (2021) PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Frontiers in Cellular Neuroscience 15.
Crossref
Crossref
Christian Bailly, Xavier Thuru & Bruno Quesnel. (2021) Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers 13:12, pages 3034.
Crossref
Crossref
Shuo Zhang, Li Wang, Mengtao Li, Fengchun Zhang & Xiaofeng Zeng. (2021) The PD-1/PD-L pathway in rheumatic diseases. Journal of the Formosan Medical Association 120:1, pages 48-59.
Crossref
Crossref
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Yuxiang Fu & Guixiang Liao. (2020) Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Ana Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, Hugo Arasanz, Luisa Chocarro, Miren Zuazo, Pilar Morente, Ruth Vera, David Escors & Grazyna Kochan. (2020) PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. International Journal of Molecular Sciences 21:16, pages 5918.
Crossref
Crossref
Cara L. Mack, David Adams, David N. Assis, Nanda Kerkar, Michael P. Manns, Marlyn J. Mayo, John M. Vierling, Mouaz Alsawas, Mohammad H. Murad & Albert J. Czaja. (2020) Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 72:2, pages 671-722.
Crossref
Crossref
Shinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi, Yashushi Kawaguchi & Masayoshi Harigai. (2020) Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity. Lupus 29:7, pages 686-696.
Crossref
Crossref
Taher Abu Hejleh, Muhammad Furqan, Zuhair Ballas & Gerald Clamon. (2019) The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Critical Reviews in Oncology/Hematology 143, pages 148-152.
Crossref
Crossref
Qun Xue, Xiaoping Li, Yanzheng Gu, Xiaozhu Wang, Mingyuan Wang, Jingluan Tian, Xiaoyu Duan, Hanqing Gao, Xiaopei Ji, Xiaoming Yan, Wanli Dong, Qi Fang & Xueguang Zhang. (2019) Unbalanced Expression of ICOS and PD-1 in Patients with Neuromyelitis Optica Spectrum Disorder. Scientific Reports 9:1.
Crossref
Crossref
Marco Sciveres, Silvia Nastasio & Giuseppe Maggiore. (2019) Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis. Frontiers in Pediatrics 7.
Crossref
Crossref
Robert O. Dillman, Gabriel I. Nistor, Bryce T. McLelland, Candace Hsieh, Aleksandra J. Poole, Andrew N. Cornforth & Hans S. Keirstead. (2019) Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines. Oncotarget 10:51, pages 5359-5371.
Crossref
Crossref
P. Hofman, S. Heeke, C. Alix-Panabières & K. Pantel. (2019) Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology 30:9, pages 1448-1459.
Crossref
Crossref
Abdulrahman A. Aljumah, Hamad Al-Ashgar, Hind Fallatah & Ali Albenmousa. (2019) Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes. Annals of Hepatology 18:3, pages 439-444.
Crossref
Crossref
Albert J. Czaja. (2018) Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. Digestive Diseases and Sciences 63:7, pages 1706-1725.
Crossref
Crossref
Giorgina Mieli-Vergani, Diego Vergani, Albert J. Czaja, Michael P. Manns, Edward L. Krawitt, John M. Vierling, Ansgar W. Lohse & Aldo J. Montano-Loza. (2018) Autoimmune hepatitis. Nature Reviews Disease Primers 4:1.
Crossref
Crossref
Colleen S. Curran & Elad Sharon. (2017) PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Seminars in Oncology 44:6, pages 428-432.
Crossref
Crossref
D Bommarito, C Hall, L S Taams & V M Corrigall. (2017) Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clinical and Experimental Immunology 188:3, pages 455-466.
Crossref
Crossref